Reagent combination, kit and method for simultaneously detecting methylation states of SEPT9, SDC2, SFRP2 and RNF180
By designing a reagent combination and kit for PCR, the methylation status of SEPT9, SDC2, SFRP2 and RNF180 can be detected simultaneously, solving the problem that multiple cancer types cannot be detected efficiently at the same time in the prior art, and achieving efficient and accurate multiple cancer diagnosis.
Patent Information
- Application Number
- CN202411100615.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-08
AI Technical Summary
Existing cancer detection methods cannot detect multiple cancer types efficiently at the same time, resulting in extended diagnosis time, increased costs and inconvenience to patients.
A reagent combination and kit are provided that simultaneously detects the methylation status of SEPT9, SDC2, SFRP2 and RNF180, including specific primers, probes and blockers, and achieves efficient detection through PCR reactions.
The detection of gene targets with as low as 10 copies/response can be detected, and the methylation ratio in the sample can be detected as low as 1%, 3%, 0.83% and 1.3% to achieve the purpose of diagnosing various cancer types. It has 90%-110% PCR reaction efficiency and good specificity.
Smart Images

Figure CN118910261A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biological detection, and specifically relates to a reagent combination, a kit and a method for simultaneously detecting the methylation status of SEPT9, SDC2, SFRP2 and RNF180. Background Art
[0002] Cancer is a multistep process driven by the accumulation of genetic mutations and alterations in epigenetic regulatory mechanisms, including DNA methylation, histone modifications, and small noncoding regulatory RNA modifications. In mammals, DNA methylation occurs at cytosine nucleotide bases adjacent to guanine nucleotide bases. In normal tissue cells, methylation occurs primarily in regions with fewer CpG dinucleotide sequences, while regions with long CpG dinucleotide sequences or also known as CpG islands, which are associated with gene expression regulation, remain unmethylated. However, under special circumstances, CpG islands undergo extensive DNA methylation, which causes changes in gene regulation and leads to tumorigenesis. Such methylation changes are found in most cancer cases. Currently, DNA methylation has been widely used as a biomarker for cancer detection because (i) DNA methylation occurs at almost all stages of cancer development, including early stages; and (ii) DNA methylation events are tissue or tumor type specific in many cancer cases.
[0003] Detection of circulating tumor DNA (ctDNA) methylation has been evaluated as a method for diagnosing cancer. Several studies have shown that cancer patients have higher levels of total free DNA (cfDNA) derived from cancer tissue in their blood circulation.
[0004] Although the current detection methods for colorectal cancer mainly rely on fecal occult blood testing and endoscopic examination methods, these methods have limited detection accuracy and are not cost-effective. The use of free methylated Septin 9 (SEPT9) gene in human peripheral blood as a marker for colorectal cancer has shown good prospects. SEPT9 is a tumor suppressor gene. The protein it encodes controls many important physiological processes, including cell division, cell membrane remodeling, and vesicle transport. These processes are involved in controlling the development of cancer cells. Under methylation conditions, the transcription and translation of the SEPT9 gene are inhibited, affecting the normal function of the SEPT9 protein and leading to abnormal cell development. Multiple studies have shown that the sensitivity of diagnosing colorectal cancer using methylated SEPT9 detection ranges from 47% to 87%, while the specificity ranges from 80% to 98%.
[0005] In addition to SEPT9, syndecan-2 (SDC2) and secreted frizzled-related protein 2 (SFRP2) have also been reported as potential biomarkers for colorectal cancer detection. Methylated SDC2 regulates the proliferation of colorectal cancer cells and inhibits apoptosis, while SFRP2 is a regulator of Wnt signaling, which regulates cell development closely related to cancer. Both SDC2 and SFRP2 have been used for cancer diagnosis. For colorectal cancer diagnosis, a sensitivity of 72.3% was achieved by examining SFRP2 methylation in plasma samples, while the sensitivity of diagnosing colorectal cancer by detecting methylated SDC2 in plasma or serum samples was 60% to 87%, with a specificity of 95%.
[0006] Several studies have shown that a gene panel consisting of SEPT9 and other genes appears to be a better and more promising method for detecting precancerous lesions and early colorectal cancer. For example, the combination of methylated SEPT9 and SDC2 increased the sensitivity of precancerous lesions detection compared with detection by methylated SEPT9 or methylated SDC2 alone. In addition, the sensitivity and specificity of the combination containing methylated SFRP2, SDC2 and other genes were 91.5% and 97.3%, respectively, which better distinguished colorectal cancer patients from healthy controls. These data show that the application of different gene panels as a method for detecting colorectal cancer in plasma samples is feasible and effective.
[0007] SFRP2 is not only associated with colorectal cancer, but also with hepatocellular carcinoma, including primary hepatocellular carcinoma, chronic hepatitis associated with hepatitis B or C virus, and cirrhosis. SFRP2 methylation occurs at all stages of liver cancer, including the early stages of cancer cell development. The study found that the methylation level of SFRP2 was highest in hepatocellular carcinoma, followed by cirrhosis and chronic hepatitis, and was lowest in normal liver. Therefore, methylated SFRP2 is not only a reliable biomarker for detecting any stage of liver cancer, but also the liver cancer stage of liver cancer patients can be determined based on the degree or level of methylation of the SFRP2 gene.
[0008] On the other hand, RING finger protein 180 (RNF180) is an important marker for gastric cancer detection. RNF180 is an E3 ubiquitin ligase that regulates cell proliferation and differentiation and is therefore a tumor suppressor that controls cancer cell development. Comparing gastric cancer patients with healthy controls, the former had a higher level of RNF180 methylation. The detection rate of methylated RNF180 gene in plasma samples of gastric cancer patients was 57.83%, while RNF180 gene methylation was not detected or only 23.81% in plasma samples of healthy controls. It has been reported that the counts of CpG methylated sites and CpG hypermethylated sites of RNF180 increase with cancer stage, indicating that methylation events of RNF180 occur in the early stages of gastric cancer. RNF180 methylation is directly related to tumor size, histological type, distant metastasis, etc. In addition, the combination of RNF180 methylation and SFRP2 methylation is a better method for diagnosing gastric cancer. This means that the combination of RNF180 and various gene components has the potential to serve as a biomarker for gastric cancer detection.
[0009] Currently available cancer marker test kits can only diagnose a single or at most two cancer types, mainly for the detection and diagnosis of colon and rectal cancer. On the other hand, many test kits use a multi-gene panel to diagnose a single type of cancer. However, in many cases, those at risk of cancer need to be diagnosed with multiple cancer types at the same time. Using existing methods, more samples need to be collected from patients and tested through different test kits in order to diagnose multiple cancer types. These will inevitably lead to problems such as prolonged diagnosis time and increased costs, which will bring inconvenience to patients. Therefore, we need to provide an advanced solution to overcome the above problems. Summary of the invention
[0010] In view of the problems existing in the prior art, the present invention provides a reagent combination, a kit and a method for simultaneously detecting the methylation status of SEPT9, SDC2, SFRP2 and RNF180. The reagent combination includes primers shown in SEQ ID NO.1-17, probes shown in SEQ ID NO.18-30 and blockers shown in SEQ ID NO.31-32. The PCR reaction efficiency of the reagent combination provided by the present invention can reach 90%-110%, and has good specificity. The reagent combination of the present invention can detect each gene target as low as 10 copies / reaction, and can detect the methylation ratios of SEPT9, SDC2, SFRP2 and RNF180 gene targets in the sample as low as 1%, 3%, 0.83% and 1.3%, respectively, to achieve the purpose of diagnosing multiple types of cancer.
[0011] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0012] On the one hand, the present invention provides a reagent combination, which can simultaneously detect the methylation status of SEPT9, SDC2, SFRP2 and RNF180, and the reagent combination includes primers, probes, and blockers.
[0013] Specifically, the primers have nucleotide sequences as shown in SEQ ID NO.1-17.
[0014] Specifically, the probe has a nucleotide sequence as shown in SEQ ID NO.18-30.
[0015] More specifically, the probe may be labeled with a fluorescent group or a quenching group at the 5' end or the 3' end.
[0016] Preferably, the fluorescent group is selected from one or more of FAM, HEX, ROX, CY5, Quasar, VIC, TET, CAL Gold 540, JOE, TAMRA, and CY3.
[0017] Further preferably, the fluorescent group is selected from one or more of FAM, HEX, ROX, CY5 and Quasar.
[0018] Preferably, the quenching group is selected from one or more of Iowa Black RQ, Iowa Black FQ, DABCYL, BHQ1, BHQ2, BHQ3, and ECLIPE.
[0019] Further preferably, the quenching group is selected from Iowa Black RQ or Iowa Black FQ.
[0020] Specifically, the blocker has a nucleotide sequence as shown in SEQ ID NO.31-32.
[0021] Preferably, the final concentration of the primers, probes and blockers is 100-1000 nM.
[0022] Preferably, the final concentration of the primer is 100-300 nM.
[0023] Preferably, the final concentration of the probe is 100-200 nM.
[0024] Preferably, the final concentration of the blocker is 1000 nM.
[0025] More preferably, the final concentrations of the primers, probes and blockers are as shown in Tables 4 to 6.
[0026] Specifically, the PCR amplification reaction conditions of the reagent combination are carried out according to the following steps:
[0027] Stage 1: 95°C for 3 min;
[0028] Stage 2: 95°C for 15 s, 60°C for 30 s (-1°C / cycle, starting from cycle 1), for 10 cycles;
[0029] Stage 3: 95°C for 15 s, 56°C for 30 s, 60°C for 30 s, for 40 cycles.
[0030] In another aspect, the present invention provides use of the above reagent combination in preparing a kit.
[0031] In one aspect, the present invention provides a kit capable of simultaneously detecting the methylation status of SEPT9, SDC2, SFRP2 and RNF180.
[0032] Specifically, the kit also includes an enzyme mixture, a primer-probe-blocker mixture, a positive control substance, and a negative control substance.
[0033] Preferably, the enzyme mixture comprises DNA polymerase, dNTP, MgCl2 and buffer.
[0034] Preferably, the positive control is a mixture of plasmid DNA of methylated SEPT9, SDC2, SFRP2, RNF180 and Actin.
[0035] Preferably, the negative control is nuclease-free water.
[0036] Specifically, the kit can simultaneously diagnose colon cancer, rectal cancer, liver cancer and gastric cancer.
[0037] Preferably, the kit diagnoses colon cancer, rectal cancer, liver cancer and gastric cancer by detecting the methylation status of SEPT9, SDC2, SFRP2 and RNF180.
[0038] In one aspect, the present invention provides a method for simultaneously detecting the methylation status of SEPT9, SDC2, SFRP2 and RNF180, wherein the method comprises using the above-mentioned reagent combination or kit.
[0039] Specifically, the method comprises the following steps:
[0040] S1. Extract cfDNA;
[0041] S2, performing bisulfite conversion on the extracted cfDNA to obtain a DNA sample;
[0042] S3, taking the reagent combination and the enzyme mixture, preparing the qPCR reaction mixture;
[0043] S4, taking the DNA sample, positive control substance, and negative control substance prepared in step S2, and adding them to the qPCR reaction mixture prepared in step S3 respectively;
[0044] S5. Execute the PCR program for detection.
[0045] Preferably, the PCR procedure described in step S5 is performed as follows:
[0046] Stage 1: 95°C for 3 min;
[0047] Stage 2: 95°C for 15 s, 60°C for 30 s (-1°C / cycle, starting from cycle 1), for 10 cycles;
[0048] Stage 3: 95°C for 15 s, 56°C for 30 s, 60°C for 30 s, for 40 cycles.
[0049] The technical effects achieved by the present invention are:
[0050] The reagent combination provided by the present invention can achieve a PCR reaction efficiency of 90%-110% and has good specificity. The reagent combination of the present invention can detect each gene target as low as 10 copies / reaction, and can detect the methylation ratios of SEPT9, SDC2, SFRP2 and RNF180 gene targets in the sample as low as 1%, 3%, 0.83% and 1.3%, respectively, to achieve the purpose of diagnosing various types of cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 Analysis of methylation levels of SEPT9 region in normal tissues and corresponding colon cancer tissues.
[0052] Figure 2 Analysis of methylation levels of SEPT9 region in normal tissues and corresponding colorectal cancer tissues.
[0053] Figure 3 Analysis of methylation levels of SEPT9 region in normal tissues and corresponding liver cancer tissues.
[0054] Figure 4 Analysis of methylation levels of SEPT9 region in normal tissues and corresponding gastric cancer tissues.
[0055] Figure 5 The figure shows the multiplex qPCR amplification of 5 different gene targets in the detection results.
[0056] Figure 6The qPCR amplification graph of SEPT9 in the range of 5E+05 to 0.5 copies / μL.
[0057] Figure 7 The qPCR amplification graph of SDC2 in the range of 5E+05 to 0.5 copies / μL.
[0058] Figure 8 The qPCR amplification graph of SFRP2 in the range of 5E+05 to 0.5 copies / μL.
[0059] Fig. 9 The qPCR amplification graph of RNF180 in the range of 5E+05 to 0.5 copies / μL.
[0060] Fig.10 This is the qPCR amplification graph of Actin in the range of 6E+05 to 6.0 copies / μL.
[0061] Fig.11 The blocker is used to measure the effect of the amplification of methylated or unmethylated templates in qPCR reactions.
[0062] Fig.12 Primers, probes and blockers are used to amplify specific methylated fragments.
[0063] Fig.13 The figure shows the effect of different qPCR reaction conditions on the qPCR amplification curve. A in the figure shows the qPCR amplification curve using the standard PCR temperature cycle program; B shows the qPCR amplification curve using the touchdown qPCR thermal cycle program. DETAILED DESCRIPTION
[0064] The present invention will be further described in detail below by way of examples. The following examples are only a part of the present invention and are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are not specifically stated, and the materials, reagents, etc. used in the following examples are all commercially available unless otherwise specified.
[0065] The experimental materials used in the present invention are shown in Table 1:
[0066] Table 1 Experimental materials
[0067] name factory Part Number cfDNA Extraction Kit Meiji Biotechnology IVD5435 Bisulfite Conversion Kit Zymo Research D5042
[0068] Basic Experimental Example 1 Whole Blood Sample Processing Method
[0069] 1. Collect 5 mL of whole blood into a test tube treated with commercially available anticoagulant EDTA.
[0070] 2. Centrifuge the whole blood sample at 1000 g for 15 minutes. After centrifugation, the plasma is in the upper layer.
[0071] 3. Transfer 2 mL of plasma to a 15 mL centrifuge tube.
[0072] Basic Experimental Example 2 Method for extracting cfDNA according to the instructions of the commercial kit
[0073] 1. Add 2 μL of carrier RNA, 100 μL of proteinase K and 100 μL of SDS into a 15 mL centrifuge tube containing 2 mL of plasma and mix well.
[0074] 2. Incubate at 55°C for 30 minutes, inverting several times.
[0075] 3. Incubate at room temperature for 5 minutes to cool the sample.
[0076] 4. Add 3.5 mL of binding solution and 100 μL of magnetic beads to the sample. Mix by inversion or vortexing for 10 minutes at room temperature. Place the tube on the magnetic stand for 5 minutes until the beads form a compact pellet. Discard the supernatant after this time.
[0077] 5. Add 1000 μL of Wash Buffer 1 and vortex for 15 seconds to resuspend the beads. Transfer the resuspended solution to a 1.5 mL microcentrifuge tube. Place the tube on a magnetic stand for 1 minute until the beads form a compact pellet. Discard the supernatant thereafter.
[0078] 6. Add 1000 μL of Wash Buffer 1 and vortex for 15 seconds to resuspend the beads. Place the tube on the magnetic stand for 1 minute until the beads form a compact pellet. Discard the supernatant thereafter.
[0079] 7. Add 1000 μL of Wash Buffer 2 and vortex for 15 seconds to resuspend the beads. Place the tube on the magnetic stand for 1 minute until the beads form a tight pellet. Discard the supernatant after this time. Repeat this wash step.
[0080] 8. Briefly centrifuge to collect the liquid in the tube. Place the tube on a magnetic rack and discard the liquid.
[0081] 9. Dry the granules at 37°C for 15 minutes.
[0082] 10. Add 25 μL of elution buffer and vortex for 5 minutes at 37°C to resuspend the beads.
[0083] 11. Place the tube on the magnetic rack for 1 minute.
[0084] 12. Transfer the supernatant containing purified DNA to a clean 1.5 mL microcentrifuge tube.
[0085] 13. The extracted cfDNA is now ready for downstream bisulfite conversion processing.
[0086] Basic Experimental Example 3 Method for Bisulfite Conversion According to the Commercial Kit Instructions
[0087] 1. Mix the ingredients in Table 2 in a 0.2 mL tube.
[0088] Table 2 Ingredients
[0089] Element Each reaction volume (μL) cfDNA extraction eluate 20 CT conversion reagent 130
[0090] 2. Mix the sample by pipetting up and down, then centrifuge to allow the liquid to reach the bottom of the tube.
[0091] 3. Transfer the tubes to a thermal cycler and follow the steps in Table 3:
[0092] Table 3 Thermal Cycle
[0093] Cycle steps Temperature(℃) time transsexual 98 10 minutes incubation 64 2.5 hours Retention / Storage 4 Up to 20 hours
[0094] 4. Add 600 μL of binding buffer and 10 μL of magnetic beads to a 1.5 mL tube.
[0095] 5. Transfer the sample from the 0.2 mL tube to the 1.5 mL tube containing the binding buffer and magnetic beads. Pipette up and down 3-6 times or vortex to mix.
[0096] 6. Allow the tube to stand at room temperature for 5 minutes, then centrifuge briefly and transfer to a magnetic rack and allow to stand for another 5 minutes or until the beads and supernatant are clear. Place the tube on the magnetic rack and remove the supernatant.
[0097] 7. Remove the tube from the magnetic stand. Add 400 μL of wash buffer to the beads. Resuspend the beads by pipetting up and down or vortexing. Briefly centrifuge the tube and place on the magnetic stand for 3 minutes or until the beads are pelleted. Remove and discard the supernatant.
[0098] 8. Add 200 μL of desulfonation buffer to the beads. Resuspend the beads by pipetting up and down or vortexing. Let the tube sit at room temperature for 15-20 minutes. At the end of the incubation, briefly centrifuge the tube and place on a magnetic stand for 3 minutes or until the beads are pelleted. Remove and discard the supernatant.
[0099] 9. Add 400 μL of wash buffer to the beads. Resuspend the beads by pipetting up and down or vortexing. Briefly centrifuge the tube and place it back on the magnetic stand for 3 minutes or until the beads are pelleted. Remove and discard the supernatant. Repeat this wash step.
[0100] 10. Transfer the tube to a heating element at 55°C for 20-30 minutes to dry the beads and remove residual wash buffer.
[0101] 11. Add 25 μL of elution buffer directly to the dried beads and resuspend using a pipette or vortexer.
[0102] 12. Heat the eluate at 55°C for 4 minutes, then centrifuge the tube briefly and transfer to a magnetic stand for 1 minute or until the beads are precipitated. Remove the supernatant and transfer to a clean 1.5 mL microcentrifuge tube.
[0103] 13. The bisulfite-converted DNA can be used for subsequent qPCR quantification (the bisulfite conversion rate of the commercially available bisulfite conversion kit used in the invention can reach 99.53%).
[0104] Example 1 A combination for simultaneously detecting the methylation status of SEPT9, SDC2, SFRP2 and RNF180
[0105] According to bioinformatics analysis, in peripheral blood, the combination of methylation status of four gene targets, SEPT9, SDC2, SFRP2 and RNF180, is associated with the incidence of colon cancer, rectal cancer, liver cancer and gastric cancer. The maplab tool was used to analyze the methylation level of the SEPT9 gene region in normal cells and the corresponding colon cancer cells, rectal cancer cells, liver cancer cells and gastric cancer cells. The results are shown in Figure 1-Figure 4 The gene regions with the greatest methylation differences between normal cells and cancer cells will be selected as qPCR amplification regions for the subsequent design of primers, probes, and blockers.
[0106] In order to improve the specific amplification and detection of the four methylated genes, the present invention designs a primer-probe-blocker mixture, and uses several pairs of primers or several probes for the amplification of each gene. For the detection of the housekeeping gene Actin, the primer sequences are shown in SEQ ID NO.16 and SEQ ID NO.17. Tables 4 to 6 list the nucleotide sequences of all primers, probes, and blockers used to detect the four methylated genes. The final concentrations of each primer, probe, and blocker in the primer-probe-blocker mixture are also listed.
[0107] Table 4 Nucleotide sequences of primers
[0108]
[0109]
[0110] Table 5 Nucleotide sequences of probes
[0111]
[0112]
[0113] Table 6 Nucleotide sequences of probes
[0114]
[0115] Example 2 qPCR reaction conditions
[0116] 1. qPCR reaction mixture
[0117] Prepare qPCR reaction mixture according to Table 7:
[0118] Table 7 Components of qPCR reaction mixture
[0119] thing Volume (μL) Final concentration 4× Primer Probe Blocker Mix 5 1× 4× Enzyme Mix 5 1× Total reaction volume 10 none
[0120] The enzyme mix described in Table 7 includes: DNA polymerase, dNTPs, MgCl2 and buffer.
[0121] 2. Touchdown qPCR Thermal Cycling Program
[0122] The touchdown qPCR thermal cycle program is shown in Table 8.
[0123] Table 8 Touchdown qPCR thermal cycling program
[0124]
[0125] Experimental Example 1 PCR analysis
[0126] 1. Experimental steps
[0127] (1) Prepare a primer-probe-blocker mixture according to Example 1. Prepare a qPCR reaction mixture according to Table 7.
[0128] (2) Aliquot 10 μL of qPCR reaction mixture into each well.
[0129] (3) Add 10 μL of bisulfite-converted DNA, positive control (plasmid DNA mixture of methylated SEPT9, SDC2, SFRP2, RNF180 and Actin), or negative control (nuclease-free water) to the wells containing the qPCR reaction mixture.
[0130] (4) Seal the well and vortex to ensure that the components of the reaction mixture are thoroughly mixed.
[0131] (5) Centrifuge the tube to remove air bubbles.
[0132] (6) Perform qPCR according to the touchdown qPCR thermal cycle program shown in Table 8.
[0133] 2. Analysis results
[0134] Figure 5It is a multiplex qPCR amplification diagram of the methylation gene targets of SEPT9, SDC2, SFRP2, RNF180 and housekeeping gene Actin of the present invention at 3000 copies / reaction plasmid DNA at the same time. Figure 6-Figure 10 The figure is a schematic diagram of the detection sensitivity results of the five methylation gene targets SEPT9, SDC2, SFRP2, RNF180 and Actin of the present invention. The amplification curves from high concentration to low concentration in the figure show the amplification system at 10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 and 10 0 The results showed that the standard curves of SEPT9, SDC2, SFRP2, RNF180 and Actin genes could reach R 2 ≥0.99, and the PCR reaction efficiency can reach 90%-110%. They all showed good PCR efficiency and linearity.
[0135] The specific detection results show (Table 9) that the detection method of the present invention has good specificity for amplifying methylated SEPT9, SDC2, SFRP2, RNF180 and Actin, but is insensitive to unmethylated DNA templates.
[0136] Table 9 Specificity test results
[0137]
[0138]
[0139] Table 10 shows the number of positive detections at 10 copies / reaction for methylated gene targets of SEPT9, SDC2, SFRP2, RNF180 and housekeeping gene Actin. The observed positive detection rate of each gene target at a minimum of 10 copies / amplification reaction was over 95%, indicating that the detection method of this reagent has a minimum detection limit of 10 copies / amplification reaction for methylated SEPT9, SDC2, SFRP2, RNF180 and housekeeping gene Actin.
[0140] Table 10 Number of positive tests at 10 copies / reaction
[0141]
[0142]
[0143] In 20 amplification reactions, the observed positive detection rate of each gene target in the methylation level test must reach 95% or above. Table 11 shows that this reagent can detect methylation levels as low as 1%, 3%, 0.83% and 1.3% for each gene target of SEPT9, SDC2, SFRP2 and RNF180 in the sample.
[0144] Table 11 Detection limits of methylation levels
[0145]
[0146]
[0147]
[0148] Experimental Example 2 Effects on amplification of methylated or unmethylated templates in qPCR reactions
[0149] 1. Preparation of detection reagents:
[0150] Detection reagent: primer-probe-blocker mixture; the primers are shown in Table 4, the probes are shown in Table 5, and the blockers are shown in Table 6.
[0151] 2. Preparation of qPCR reaction mixture:
[0152] The components of the qPCR reaction mixture are shown in Table 12.
[0153] Table 12 Components of qPCR reaction mixture
[0154] thing Volume (μL) Final concentration 4× Detection Reagent 1 5 1× 4× Enzyme Mix 5 1× Total reaction volume 10 none DNA or positive control or negative control 10 none
[0155] 3. The methylated DNA template was the plasmid DNA of methylated SEPT9, SDC2, SFRP2 and RNF180. The unmethylated DNA template was the plasmid DNA of unmethylated SEPT9, SDC2, SFRP2 and RNF180.
[0156] 4. Aliquot 10 μL of qPCR reaction mixture into each well.
[0157] 5. Add 10 μL of 300 copies / μL plasmid DNA, positive control or negative control (nuclease-free water) to the wells containing the reaction mixture.
[0158] 6. Seal the well and vortex to ensure that the reaction mixture components are thoroughly mixed.
[0159] 7. Centrifuge the tube to remove air bubbles.
[0160] 8. Perform qPCR according to the touchdown qPCR thermal cycling program shown in Table 8.
[0161] Effects of blocking agents on the amplification of methylated or unmethylated templates in qPCR reactions Fig.11 As shown in the figure, adding a blocker to the qPCR reaction does not affect the amplification of the methylated template. The blocker not only improves the specificity of the amplification of the methylated template, but also inhibits the amplification of the non-methylated template.
[0162] like Fig.12 As shown in A in the figure, the blocker cannot bind to the methylated template, and the probe binds to the methylated template, causing the amplification process to produce a specific signal. Fig.12 As shown in B, the blocker can block the binding of the probe to the non-methylated template, thereby preventing the generation of an amplification signal.
[0163] Experimental Example 3 Effect of qPCR reaction conditions on qPCR amplification curve
[0164] 1. Prepare a primer-probe-blocker mixture according to Example 1. Prepare a qPCR reaction mixture according to Table 7.
[0165] 2. Aliquot 10 μL of qPCR reaction mixture into each well.
[0166] 3. Add 10 μL of positive control or negative control (nuclease-free water) to the wells containing the reaction mixture.
[0167] 4. Seal the well and vortex to ensure that the reaction mixture components are thoroughly mixed.
[0168] 5. Centrifuge the tube to remove air bubbles.
[0169] 6. Perform qPCR according to the thermal cycle program
[0170] (1) performing qPCR according to a standard PCR temperature cycling program (Table 13);
[0171] (2) Perform qPCR according to the touchdown qPCR thermal cycle program shown in Table 8.
[0172] Table 13 Standard PCR temperature cycle program
[0173]
[0174] Fig.13 The standard PCR temperature cycling program ( Fig.13 A) or touchdown qPCR thermal cycle program ( Fig.13B) Two different qPCR amplification curves. The touchdown PCR thermal cycle program increased the amplification sensitivity of methylated SEPT9, SDC2, SFRP2, RNF180 and housekeeping gene Actin, not only increasing the fluorescence intensity but also reducing the Ct value.
[0175] The above detailed description is a specific description of one of the feasible embodiments of the present invention, and the embodiment is not intended to limit the scope of the present invention. It should be pointed out that any equivalent implementation or change that does not deviate from the present invention should be included in the scope of the technical solution of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached requirements.
Claims
1. A reagent combination, characterized in that: The reagent combination can simultaneously detect the methylation status of SEPT9, SDC2, SFRP2 and RNF180, and the reagent combination includes primers, probes, and blockers; the primers have nucleotide sequences as shown in SEQ ID NO.1-17.
2. The reagent combination according to claim 1, characterized in that The probe has a nucleotide sequence as shown in SEQ ID NO.18-30.
3. The reagent combination according to claim 2, characterized in that: The probe may be labeled with a fluorescent group or a quenching group at the 5' end or the 3' end.
4. The reagent combination according to claim 3, characterized in that: The fluorescent group is selected from one or more of FAM, HEX, ROX, CY5, Quasar, VIC, TET, CAL Gold 540, JOE, TAMRA, and CY3.
5. The reagent combination according to claim 4, characterized in that: The fluorescent group is selected from one or more of FAM, HEX, ROX, CY5 and Quasar.
6. The reagent combination according to claim 3, characterized in that: The quenching group is selected from one or more of Iowa Black RQ, Iowa Black FQ, DABCYL, BHQ1, BHQ2, BHQ3, and ECLIPE.
7. The reagent combination according to claim 6, characterized in that: The quenching group is selected from Iowa Black RQ or Iowa Black FQ.
8. The reagent combination according to claim 1, characterized in that: The blocker has a nucleotide sequence as shown in SEQ ID NO.31-32.
9. The reagent combination according to claim 1, characterized in that: The final concentrations of the primers, probes and blockers are 100-1000 nM.
10. The reagent combination according to claim 9, characterized in that: The final concentration of the primer is 100-300 nM; the final concentration of the probe is 100-200 nM; and the final concentration of the blocker is 1000 mM.
11. The reagent combination according to claim 1, characterized in that: The PCR amplification reaction conditions of the reagent combination are carried out as follows: Stage 1: 95°C for 3 min; Stage 2: 95°C for 15 s, 60°C for 30 s, -1°C / cycle, starting from cycle 1, for 10 cycles; Stage 3: 95°C for 15 s, 56°C for 30 s, 60°C for 30 s, for 40 cycles.
12. Use of the reagent combination according to any one of claims 1 to 11 in preparing a kit.
13. A kit, characterized in that: The kit comprises the reagent combination according to any one of claims 1 to 11, and the kit can simultaneously detect the methylation status of SEPT9, SDC2, SFRP2 and RNF180.
14. The kit according to claim 13, characterized in that The kit also includes an enzyme mixture, a positive control substance or a negative control substance.
15. The kit according to claim 13, characterized in that The kit can diagnose colon cancer, rectal cancer, liver cancer and gastric cancer at the same time.
16. The kit according to claim 15, characterized in that The kit diagnoses colon cancer, rectal cancer, liver cancer and gastric cancer by detecting the methylation status of SEPT9, SDC2, SFRP2 and RNF180.
17. A method for simultaneously detecting the methylation status of SEPT9, SDC2, SFRP2 and RNF180, characterized in that: The method comprises using the reagent combination described in any one of claims 1-11 or the kit described in any one of claims 13-16.
18. The method according to claim 17, characterized in that The method comprises the following steps: S1. Extract cfDNA; S2, performing bisulfite conversion on the extracted cfDNA to obtain a DNA sample; S3, taking the reagent combination and the enzyme mixture, preparing the qPCR reaction mixture; S4, taking the DNA sample prepared in step S2, and the positive control substance and the negative control substance, and adding them to the qPCR reaction mixture prepared in step S3 respectively; S5. Execute the PCR program for detection.
